3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
113
Colonic Neoplasms
30
Neoplasm Metastasis
28
Rectal Neoplasms
27
Neoplasms
27
Carcinoma, Non-Small-Cell Lung
14
Esophageal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Pancreatic Neoplasms
9
Head and Neck Neoplasms
9
Lung Neoplasms
8
Cholangiocarcinoma
7
Carcinoma, Squamous Cell
6
Breast Neoplasms
6
Colorectal Cancer Metastatic
5
Carcinoma
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Inflammatory Breast Neoplasms
3
Gastrointestinal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Kidney Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Interventions
Cisplatin
115
Radiotherapy
83
Paclitaxel
77
Fluorouracil
61
Carboplatin
41
Drug Therapy
34
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Oxaliplatin
23
Neoadjuvant Therapy
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
17
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
15
Leucovorin
15
Nivolumab
14
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
anlotinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Squamous Cell Carcinoma
×
Panitumumab
×
Clear all
NCT01627379
2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3
Terminated
300 enrolled